{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"8"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"20"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"7"}],"title":"Progressive Disease"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"8"}],"title":"Unevaluable"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"43"}],"units":"Participants"}],"description":"Objective Response Rate (ORR), defined as a Complete Response (CR) or Partial Response (PR) utilizing:\n\n1. RECIST criteria v.1.1 (Endometrial \\& Ovarian Cancers):\n\n   * CR: Disappearance of all target \\& non-target lesions (+ normalization of tumor marker level)\n   * PR: \\>/= 30% decrease in sum of the longest diameters of target lesions (from baseline) \\& no new lesions\n2. RANO criteria (GBM patients):\n\n   * CR:\n\n     * Disappearance of all enhancing measurable \\& non-measurable disease (sustained \\>/= 4 wks)\n     * No new lesions\n     * No steroids (physiologic replacement doses only)\n     * Stable or improved non-enhancing lesions\n     * Clinically stable or improved\n   * PR:\n\n     * \\>/= 50% decrease compared to baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions (sustained \\>/= 4 wks)\n     * No progression of non-measurable disease\n     * No new lesions\n     * Steroid \\</= dose at time of baseline scan\n     * Stable or improved non-enhancing lesions\n     * Clinically stable or improved","groups":[{"description":"3 mg MLN0128 Daily","id":"OG000","title":"Dose Level 1"},{"description":"4 mg MLN0128 Daily","id":"OG001","title":"Dose Level 2"},{"description":"5 mg MLN0128 Daily","id":"OG002","title":"Dose Level 3 (MTD)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}